South Texas Pediatric Minority Based CCOP

描述(由申请人提供)：南得克萨斯州以少数族裔为基础的社区临床肿瘤学计划(STP-MB-CCOP)成立于1990年，目前正处于其资助的第17个年头，是美国两个唯一的儿科CCOP之一。STP-MB-CCOP的首席研究员传统上是德克萨斯大学圣安东尼奥健康科学中心(UTHSCSA)儿科血液学/肿瘤科的内科医生。STP-MB-CCOP由4家儿科机构组成：1)克里斯图斯·圣罗莎儿童医院(CSRCH)(德克萨斯州圣安东尼奥)；2)德里斯科尔儿童医院(德克萨斯州科珀斯克里斯蒂)；3)卫理公会儿童医院(圣安东尼奥)；4)威尔福德·霍尔医疗中心(德克萨斯州圣安东尼奥)美国陆军儿科肿瘤学项目。 STP-MB-CCOP将继续为南得克萨斯州受癌症影响的青年人口提供获得最高标准的护理(即获得临床试验)的机会。此外，它将继续在涉及南得克萨斯州人口特有的健康和社会经济问题的以人口为基础的研究方面扩大其翅膀。 它将以提供癌症护理的孤儿(即患有癌症的青少年和年轻人)为目标，以了解和消除妨碍他们获得临床试验和生存的障碍。 它将集中为居住在下里奥格兰德山谷的儿科癌症患者提供临床试验。 它将通过解决以下问题进一步评估肥胖对所有患者生存的影响：1)肥胖的遗传学；2)肥胖对ALL发展的可能影响；3)肥胖对肝功能和用于治疗ALL的化疗药物新陈代谢的影响；以及4)肥胖对所有幸存者日后糖尿病和心血管疾病发展的影响。 它将作为临床基础，对边境人群中的儿科癌症人群进行遗传学研究，包括遗传混合和影响癌症风险和结果的基因的多态性研究。 它将被用于开发更多的试点研究，以解决南得克萨斯州受癌症影响的青年人口的独特性(生物或社会经济)。

DESCRIPTION (provided by applicant): The South Texas Pediatric Minority-Based Community Clinical Oncology Program (STP-MB-CCOP) was first formed in 1990, and is currently in its 17th year of funding and is one of two solely pediatric CCOPs in the United States. The Principal Investigator of the STP-MB-CCOP has traditionally been a physician in the Division of Pediatric Hematology/Oncology of the University of Texas Health Science Center at San Antonio (UTHSCSA). The STP-MB-CCOP operates as a consortium of 4 pediatric institutions: 1) CHRISTUS Santa Rosa Children's Hospital (CSRCH) (San Antonio, TX); 2) Driscoll Children's Hospital (Corpus Christi, TX); 3) Methodist Children's Hospital (San Antonio, TX), and 4) the U.S. Army pediatric oncology program at Wilford Hall Medical Center (San Antonio, TX). The STP-MB-CCOP will continue to provide access to the highest standard of care (i.e. access to clinical trials) to the youth population of South Texas affected by cancer. In addition, it will continue to expand its wings in regards to population-based studies dealing with health and socio-economic issues specific to the population of South Texas. It will target the orphans of cancer care delivery (i.e. adolescents and young adults with cancer) in order to understand and abolish the barriers interfering with their access to clinical trials and survival. It will concentrate on bringing access to clinical trials to pediatric cancer patients residing in the Lower Rio Grande Valley. It will further assess the impact of obesity on the survival of ALL patients by addressing issues such as: 1) genetics of obesity; 2) possible impact of obesity on the development of ALL; 3) impact of obesity on liver function and metabolism of chemotherapy agents used to treat ALL; and 4) impact of obesity on later development of diabetes and cardiovascular disease in ALL survivors. It will serve as a clinical base for genetic studies characterizing the pediatric cancer population in border population including genetic admixture and polymorphism studies in genes influencing both cancer risks and outcomes. It will be used to develop additional pilot studies that will address the uniqueness (biologic or socio-economic) of the youth population of South Texas affected by cancer.